Acalabrutinib with bendamustine and rituximab is now an FDA-approved treatment for patients with previously untreated mantle ...

Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...

Financially risky OS Therapies has potential with mid-stage immunotherapy for osteosarcoma, but faces funding challenges and ...

High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced ...

For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.

The study met its primary endpoint in enhancing event-free survival over 12 months when compared to historical control groups ...

In recent trading, OS Therapies Inc (OSTX) stock price has shown some volatility, fluctuating -11.02% over the last five trades and -2.24% over the past 30 trades. This represents a notable shift from ...

With positive data in hand from its phase IIb trial testing immunotherapy candidate OST-HER2 in osteosarcoma, OS Therapies ...

During a Case-Based Roundtable® event, Joshua K. Sabari, MD, continued discussion of key outcomes from the MARIPOSA trial and ...

HER2 shows promise in Phase 2b osteosarcoma trial, with improved event-free survival at 12 months; company plans to pursue ...

OS Therapies shares Phase 2b trial results showing OST-HER2 improves survival rates in rare metastatic osteosarcoma, surpassing historical controls.

OS Therapies shares surged Wednesday after the biotech company reported positive data from a clinical trial for its cancer treatment OST-HER2. Shares of the N.Y., clinical-stage biotechnology company ...